- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Overcoming Key Operational Challenges in Integrating Bispecific Therapies
Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.
EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology
EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals
EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care
EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access
EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations
EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies
Video content above is prompted by the following:
- What are the most common logistical challenges you encounter when implementing bispecific therapies?
- What are the primary barriers that smaller community practices face in operationalizing bispecific antibody treatments?
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic
March 18th 2025The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.
Read More
